{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:32:01Z","timestamp":1761514321539},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Although most of non-small cell lung cancer (NSCLC) patients with ROS1-fusions respond to crizotinb, acquired resistance eventually develop. The next-generations of ROS1 inhibitors have made some achievements, but the effects of immunotherapy have not been explored.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 44-year-old Chinese women presented with cough and dyspnea with a history of advanced lung adenocarcinoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>A PET\/CT scan revealed primary tumors in bilateral lung lobes and multiple metastases in lymph nodes and bones. And ultrasound-guided left cervical lymph node biopsy revealed the pathological diagnosis was poor differentiated lung adenocarcinoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patients was started to be treated with 4 cycles of pemetrexed, carboplatin and bevacizumab, followed by one cycle of docetaxel, cisplatin and bevacizumab. As the ROS1-fusion was found by next generation sequencing, the patient received crizotinib treatment about 3 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After 5 cycles of chemotherapy, CT scans revealed increased size of bilateral lobe nodules indicative of progressive disease (PD). Then the patient received treatment of crizotinib and his progression-free survival reached 3 months. Due to uncontrollable disease progression, the patient expired.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>The genetic profile of NSCLC patients might be altered in various therapeutic processes. Thus, repeated genetic testing might be important at each progression. Moreover, immunotherapy might be a powerful weapon to overcome the resistance to Tyrosine kinase inhibitors (TKIs) in future.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000013797","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T19:17:37Z","timestamp":1545938257000},"page":"e13797","source":"Crossref","is-referenced-by-count":3,"title":["Elevation of tumor mutation burden in ROS1-fusion lung adenocarcinoma resistant to crizotinib"],"prefix":"10.1097","volume":"97","author":[{"given":"Tao","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J Clin Oncol"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1200\/JCO.2016.71.3701","article-title":"Open-label, multicenter, phase II study of ceritinib in patients with non\u2013small-cell lung cancer harboring ROS1 rearrangement","volume":"35","author":"Sun Min Lim","year":"2017","journal-title":"J Clin Oncol"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and alk inhibitor entrectinib: combined results from two phase I Trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"issue":"(Suppl 5)","key":"R5-20230914","doi-asserted-by":"crossref","first-page":"v295","DOI":"10.1093\/annonc\/mdx371","article-title":"Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II)","volume":"28","author":"Retz","year":"2017","journal-title":"Ann Oncol"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1200\/JCO.2011.39.3744","article-title":"Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer","volume":"30","author":"Bai","year":"2012","journal-title":"J Clin Oncol"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1215530","article-title":"Acquired resistance to crizotinib from a mutation in CD74-ROS1","volume":"368","author":"Awad","year":"2013","journal-title":"N Engl J Med"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1158\/1078-0432.CCR-16-0917","article-title":"Crizotinib-resistant ROS1 mutations reveal a predictive kinase inhibitor sensitivity model for ROS1- and ALK-rearranged lung cancers","volume":"22","author":"Facchinetti","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jtho.2016.04.001","article-title":"An Activating KIT mutation induces crizotinib resistance in ROS1-positive lung cancer","volume":"11","author":"Dziadziuszko","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/j.jtho.2017.11.125","article-title":"Appearance of a BRAF mutation conferring resistance to crizotinib in non-small cell lung cancer harboring oncogenic ROS1 fusion","volume":"13","author":"Watanabe","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"e13120","DOI":"10.1200\/JCO.2017.35.15_suppl.e13120","article-title":"Mutational profiling of Chinese ROS1 positive non-small cell lung cancer patients with required resistant to crizotinib by next generation sequencing","volume":"35","author":"Wang","year":"2017","journal-title":"J Clin Oncol"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"9017","DOI":"10.1200\/JCO.2016.34.15_suppl.9017","article-title":"Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1\/PD-L1 targeted therapies","volume":"34","author":"Spigel","year":"2016","journal-title":"J Clin Oncol"},{"key":"R15-20230914","article-title":"Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers","author":"Offin","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.resinv.2018.04.004","article-title":"A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation","volume":"56","author":"Shimada","year":"2018","journal-title":"Respir Investig"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201812280-00041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:06:03Z","timestamp":1694718363000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201812280-00041"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":16,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000013797","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}